The aim of the present work is to evaluate the in vitro immunocompatibility of an elastomeric material with feasible applications in the cardiovascular field. In particular, since it is well known that surface chemistry and topography play a key role in the foreign body response, their influence on human monocytes was evaluated. The material, constituted by a poly(ether)urethane (PEtU) and a polydimethylsiloxane (PDMS), was synthesized to manufacture films and small-diameter vascular grafts with three different surface topographical features, smooth, rough and porous, and siloxane rates, 10, 30 and 40. Human THP-1 monocytes have been cultured for 72 h on the films and human blood has been circulating for 2 h into the grafts to assess leukocyte adhesion and cytokine releases. Materials extracts were utilized to evaluate monocyte apoptosis. Smooth films showed lower cell adhesion degrees than rough and porous ones. All the PEtU-PDMS (poly(ether)urethane-polydimethylsiloxane) films and vascular grafts induced a narrow inflammatory response, as demonstrated by slight cytokine secretion levels, in particular samples with the highest PDMS contents (30 and 40%) induced the lowest IL-1b secretion. Moreover, an absence of monocyte apoptosis advises that the negligible release values have not to be ascribed to material toxicity. In the end, surface topography showed to affect only monocyte adhesion while siloxane content the cytokine release. Therefore, the possibility to modify the above tested parameters during material synthesis and manufacture could allow to bound the inflammatory potency of the PEtU-PDMS devices and render them excellent candidates for cardiovascular reconstruction.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.